FORMYL PEPTIDE RECEPTOR-LIKE 1 AGONIST, WKYMVM

Product NameFORMYL PEPTIDE RECEPTOR-LIKE 1 AGONIST, WKYMVM
CAS187986-17-0
MFC41H61N9O7S2
MW856.11
EINECS
MOL File187986-17-0.mol

Chemical Properties

Boiling point	1269.6±65.0 °C(Predicted)
Density	1.268±0.06 g/cm3(Predicted)
storage temp.	-20°C
solubility	H2O: >2mg/mL
form	powder
pka	9.82±0.15(Predicted)
color	white to off-white
Water Solubility	Soluble to 2 mg/ml in water
Sequence	Trp-Lys-Tyr-Met-Val-{d-Met}-NH2

Safety Information

WGK Germany	3
Storage Class	11 - Combustible Solids

Usage And Synthesis

Uses

WKYMVm is a lipoxin A4 receptor and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2.

in vivo

WKYMVm (4 mg/kg; Intraperitoneal injection; 3 times; 24 h interval) has a protective effect in rat spinal cord injury model^[3].
WKYMVm (2.5 mg/kg; Intraperitoneal injection; 4 days) can alleviate hyperoxy-induced lung injury in neonatal mice^[4].
WKYMVm (8 mg/kg; Subcutaneous injection; Once every two days; 2-5 weeks) improves obesity in high-fat fed mouse models^[5].

Animal Model:	Adult female Sprague-Dawley rats (200-220 g) with spinal cord injury^[3]
Dosage:	4 mg/kg
Administration:	Intraperitoneal injection (i.p.); 3 times with 24 hours intervals
Result:	Reduce structural disorders and neuronal loss. Reduced the phosphorylation of ERK1/2 and NF-κB p65 but not p38.

Animal Model:	Normoxia or hyperoxic treated newborn mouse pups of C57/BL6^[4]
Dosage:	2.5 mg/kg
Administration:	Intraperitoneal injection (i.p.); daily from postnatal day (P) 5 to P8.
Result:	Significantly attenuated hyperoxia-induced lung inflammation, as evidenced by increased inflammatory cytokines, neutrophils, and alveolar macrophages, and resultant lung injuries, which included impaired alveolarization and angiogenesis, an increased number of apoptotic cells, and reduced levels of growth factors in vivo, such as vascular endothelial growth factor and hepatocyte growth factor.

Animal Model:	High fat diet treated male wild-type C57BL/6N mice aged 8 weeks old (21±2g)^[5]
Dosage:	8mg/kg
Administration:	Subcutaneous injection (i.h.); once every 2days; 2 or 5 weeks
Result:	Significantly attenuated body weight gain, food intake and increased insulin sensitivity. Markedly ameliorated HFD-induced hepatic steatosis and adipose tissue hypertrophy. Improved lipid metabolism in adipose tissue. Improved leptin signalling in the hypothalamus.

storage

Store at -20°C

FORMYL PEPTIDE RECEPTOR-LIKE 1 AGONIST, WKYMVM Supplier

FORMYL PEPTIDE RECEPTOR-LIKE 1 AGONIST, WKYMVM manufacturers

Related Product Information

Send Inquriy